Replies to post #1718 on Biotech Values

[drbio45]

Talking about deals

Indevus made what I think was a great deal. They received 30 million up front and 120 million upon approval which can happen in 2 months because their data looks very clean

The side effect profile matches up very well against detrol, the leader. An unknown fact about detrol is that it is an acetylcholine inhibitor. Overactive bladder is a disease mostly affecting the elderly. The elderly tends to lose their memory and acetylcholine inhibitors affects memory in a negative way. Indevus' drug doesn't cross the blood brain barrier. I consider this a huge advantage. I hope they get it on the label.

The only advantage detrol has is that it is a once a day pill. Indevus' pill is twice a day. I would think for the better side effect benefit it would pay to swallow a pill when you go to sleep.